Abstract
As a response to the pandemic caused by SARS-Cov-2 virus, on 15 March, 2020, the Republic of Serbia introduced comprehensive anti-epidemic measures to curb COVID-19. After a slowdown in the epidemic, on 6 May, 2020, the regulatory authorities decided to relax the implemented measures. However, the epidemiological situation soon worsened again. As of 7 February, 2021, a total of 406,352 cases of SARSCov-2 infection have been reported in Serbia, 4,112 deaths caused by COVID-19. In order to better understand the epidemic dynamics and predict possible outcomes, we have developed an adaptive mathematical model SEAIHRDS (S-susceptible, E-exposed, A-asymptomatic, I-infected, H-hospitalized, R-recovered, D-dead due to COVID-19 infection, S-susceptible). The model can be used to simulate various scenarios of the implemented intervention measures and calculate possible epidemic outcomes, including the necessary hospital capacities. Considering promising results regarding the development of a vaccine against COVID-19, the model is extended to simulate vaccination among different population strata. The findings from various simulation scenarios have shown that, with implementation of strict measures of contact reduction, it is possible to control COVID-19 and reduce number of deaths. The findings also show that limiting effective contacts within the most susceptible population strata merits a special attention. However, the findings also show that the disease has a potential to remain in the population for a long time, likely with a seasonal pattern. If a vaccine, with efficacy equal or higher than 65%, becomes available it could help to significantly slow down or completely stop circulation of the virus in human population.
The effects of vaccination depend primarily on: 1. Efficacy of available vaccine(s), 2. Prioritization of the population categories for vaccination, and 3. Overall vaccination coverage of the population, assuming that the vaccine(s) develop solid immunity in vaccinated individuals. With expected basic reproduction number of Ro=2.46 and vaccine efficacy of 68%, an 87% coverage would be sufficient to stop the virus circulation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Since no sensitive information, personal data and living subjects were used in this study, it was not necessary to obtain the consent of any competent body. This study is the result of mathematical modeling based on publicly available population data and data published in the scientific literature.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used to support the findings of this study are included within the article and can be used without restriction.
